Teva's Bonds Rally on News of $4.35bn US Opioid Crisis Settlement
Teva to Repay Due Loans with Junk Bond Private Offering | Ctech
Teva Nailed With S&P Downgrade - TheStreet
Why This Teva Pharmaceuticals Analyst Is Turning Bullish 'The Most Room To Re-Rate' - Teva Pharmaceutical Indus (NYSE:TEVA) - Benzinga
S&P Global Ratings affirms Teva Pharmaceutical Industries at "BB-" (Local Currency LT credit rating); outlook stable
Short interest in Teva Pharmaceutical Industries Limited (NYSE:TEVA) has decreased significantly. - Best Stocks
Teva Bonds: 8.8% Yield To Maturity Understates Upside | Nasdaq
Teva's Working With Evercore to Review Debt Options - Bloomberg
Teva Announces New Environmental, Social and Governance (ESG) Strategy and Goals in 2020 Report | Business Wire
Teva woes deepen as Fitch cuts credit rating to junk | The Times of Israel
Tear Sheet: Teva Pharmaceuticals Faces Pressure From Competing Generics, Seeks to Delever Quickly After Actavis Acquisition - Reorg
Teva teeters on junk rating as sell off in bonds accelerates
Credit Rating Process | A Complete Beginner's Guide
Idea of the Week: Teva Pharmaceutical—The Top Leader in Generic Drugs | Bondsupermart
Why Teva's Stock Could Crash Another 50% | BioSpace
Teva Receives A- Rating from Fitch Ratings with a Stable Outlook Jerusalem, Israel, December 13, 2012 - Teva Pharmaceutical Indu
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Sees Significant Decrease in Short Interest - MarketBeat
CSRWire - Teva Becomes First Pharmaceutical Company to Execute Sustainability-Linked Bond Tied to Both Climate and Access to Medicine Targets
Teva Announces $3,500,000,000 Debt Tender Offers for Notes Due 2022-2024 | Business Wire
S&P cuts Teva's rating on rising litigation risks
Teva (circa 20 bond in Usd, Eur, Chf) 2.8% 2023 US88167AAD37, 3.15% 2026 US88167AAE10, 6.15% 2036 US88163VAD10 | Page 3 | Quelli Che Investono
S&P: Teva faces greatest liability in US antitrust suit - Globes
Israeli company Teva Pharmaceutical stocks drop nearly 18% - The Jerusalem Post
